Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | ITGAV | P06756 | 3/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781322 | 0.91 | KLK5 (0.46) | ACEITGAVITGB6PTPN1CTSS | |
| SCHEMBL5781320 | 0.91 | KLK5 (0.46) | ACEITGAVITGB6PTPN1CTSS | |
| SCHEMBL9743083 | 0.86 | ACE (0.57) | ACEITGAVPTPN1ITGB3ITGA2B | |
| SCHEMBL9743071 | 0.86 | ACE (0.57) | ACEITGAVPTPN1ITGB3ITGA2B | |
| SCHEMBL5781496 | 0.85 | KDM4E (0.48) | ITGAVITGB3ITGA2BPPARAPPARG | |
| SCHEMBL4068384 | 0.84 | KLK5 (0.48) | ACEPTPN1CTSSCTSKCTSB | |
| SCHEMBL18262463 | 0.77 | ACE (0.52) | ACEITGAVPTPN1ITGB3ITGA2B | |
| SCHEMBL18262461 | 0.77 | ACE (0.52) | ACEITGAVPTPN1ITGB3ITGA2B | |
| SCHEMBL5782289 | 0.76 | PPARG (0.49) | PPARAPPARGPPARDKDM4EMAPT | |
| SCHEMBL5782284 | 0.76 | PPARG (0.49) | PPARAPPARGPPARDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327027-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3327027-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3327027-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2780039-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2780039-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9249186-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2015-10-29 | — | — | US | disclosed |
| US-9138486-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-1114028-B1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | AVENTIS PHARMA LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-6608084-B1 | Treatment of human or non-human animal patient suffering from, or subject to, condition which can be ameliorated by administration of inhibitor of alpha 4 beta 1 mediated cell adhesion | AVENTIS PHARMA LTD. (GB) | 2003-08-19 | — | — | US | disclosed |
| EP-1114028-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | Aventis Pharma Limited (GB) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015612-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | AVENTIS PHARMA LIMITED (GB) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | ACE 2943/4885ITGAV 248/4885ITGB6 579/4885 |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | ACE 2943/4885ITGAV 248/4885ITGB6 579/4885 |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | ACE 2943/4885ITGAV 248/4885ITGB6 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.